(duplicate) Quantification of lamellar bodies in healthy sputum
Research type
Research Study
Full title
Quantification of lamellar bodies in healthy sputum.
IRAS ID
203649
Contact name
Steve Bicknell
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Duration of Study in the UK
0 years, 2 months, 21 days
Research summary
This study aims to compare sputum from healthy controls with cystic fibrosis (CF) sputum. The hypothesis is that there is a quantitative or qualitative difference in sputum lamellar bodies between these groups.
Subjects will be recruited by the CF team. They will be NHS staff or patient relatives. They will be given a participant information leaflet and at least 24 hours to consider this before giving written informed consent. This will be taken by a member of the CF team.
The participant will have one visit to Queen Elizabeth University Hospital (QEUH) lasting around 60 minutes. Sputum will be collected from healthy participants using nebulised saline. This means breathing salty water through a mask, which encourages coughing and sputum production. Inclusion criteria are that participants are aged 16 or older, non-smokers, able to give informed consent. Exclusion criteria are those with underlying respiratory disease, smokers, intercurrent respiratory illness, evidence of respiratory disease on breathing tests. Physical examination, oxygen levels and breathing tests will be performed prior to nebulised saline, and repeated during and after sputum induction. Sputum will be collected and transferred to Glasgow University for analysis. This is to measure numbers of particles and levels of inflammation in samples.Lamellar bodies are particles which store surfactant, fat which lines the airways. They may have roles in regulating inflammation and infection in the lungs and may affect the “stickiness” of sputum.
Sputum contains compounds which reflect the physiological environment of the lung. It can be collected easily and non-invasively. Pilot work suggests that lamellar bodies are detectable in sputum. They could therefore contribute to monitoring of the disease, providing a potential therapeutic target.
CF sputum will be collected from patients attending the Adult Cystic Fibrosis Unit at QEUH under the NHSGGC Biorepository Surplus Tissue Consent. No separate consent is required.REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
16/YH/0172
Date of REC Opinion
20 Apr 2016
REC opinion
Favourable Opinion